For how we live.
In an early-phase trial of 136 previously treated patients, daraxonrasib produced responses in 31–37% depending on dose — but 54% had a serious side effect, and this is a phase 1–2 study.
Fine particulate exposure in seven Amazonian capitals was tied to about 5,472 circulatory and 2,621 respiratory deaths over six years. A separate analysis finds cardiac mortality rising with forest loss.
A comparison of FDA, EMA and ANVISA decisions from 2020 to 2024 finds Brazilian approvals arriving about a year later. A second study clocks the wait for public-system financing in years, not months.
Emergency restrictions came into force on 13 December when the index passed 450. The more telling number is how many days the city has now spent in a category that was meant to be exceptional.